Radiomic biomarkers of tumor immune biology and immunotherapy response

Sanduleanu, 2018, Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score, Radiother Oncol, 127, 349, 10.1016/j.radonc.2018.03.033 Lambin, 2013, Predicting outcomes in radiation oncology–multifactorial decision support systems, Nat Rev Clin Oncol, 10, 27, 10.1038/nrclinonc.2012.196 Aerts, 2014, Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nat Commun, 5 Lambin, 2017, Radiomics: The bridge between medical imaging and personalized medicine, Nat Rev Clin Oncol, 14, 749, 10.1038/nrclinonc.2017.141 Gillies, 2016, Radiomics: Images are more than pictures, they are data, Radiology, 278, 563, 10.1148/radiol.2015151169 Parekh, 2016, Radiomics: a new application from established techniques, Expert Rev. Precis. Med. drug Dev., 1, 207, 10.1080/23808993.2016.1164013 Bai, 2016, Imaging genomics in cancer research: Limitations and promises, Br J Radiol, 89, 20151030, 10.1259/bjr.20151030 Bodalal, 2019, Radiogenomics: bridging imaging and genomics, Abdom. Radiol., 44, 1960, 10.1007/s00261-019-02028-w Segal, 2007, Decoding global gene expression programs in liver cancer by noninvasive imaging, Nat Biotechnol, 25, 675, 10.1038/nbt1306 Gevaert, 2012, Non-Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data—Methods and Preliminary Results, Radiology, 264, 387, 10.1148/radiol.12111607 Lambin, 2012, Radiomics: Extracting more information from medical images using advanced feature analysis, Eur J Cancer, 48, 441, 10.1016/j.ejca.2011.11.036 Aerts, 2016, The Potential of Radiomic-Based Phenotyping in Precision Medicine, JAMA Oncol, 2, 1636, 10.1001/jamaoncol.2016.2631 Fridman, 2017, The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol, 14, 717, 10.1038/nrclinonc.2017.101 Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 DeNardo, 2011, Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy, Cancer Discov, 1, 54, 10.1158/2159-8274.CD-10-0028 Kaneda, 2016, PI3Kγ is a molecular switch that controls immune suppression, Nature, 539, 437, 10.1038/nature19834 Zitvogel, 2008, Immunological aspects of cancer chemotherapy, Nat Rev Immunol, 8, 59, 10.1038/nri2216 Zitvogel, 2011, Immune parameters affecting the efficacy of chemotherapeutic regimens, Nat Rev Clin Oncol, 8, 151, 10.1038/nrclinonc.2010.223 Balermpas, 2014, Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer, Br J Cancer, 110, 501, 10.1038/bjc.2013.640 Hamid, 2011, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, J. Transl. Med., 9, 204, 10.1186/1479-5876-9-204 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Topalian, 2012, Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Ma, 2019, How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy, Am J Cancer Res, 9, 1546 Nair, 2012, Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer, Cancer Res, 72, 3725, 10.1158/0008-5472.CAN-11-3943 Tunali, 2019, Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report, Lung Cancer, 129, 75, 10.1016/j.lungcan.2019.01.010 Jreige, 2019, 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer, Eur J Nucl Med Mol Imaging, 46, 1859, 10.1007/s00259-019-04348-x Evangelista, 2019, 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy, Nucl Med Commun, 40, 802, 10.1097/MNM.0000000000001025 Seban, 2020, Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors, Eur J Nucl Med Mol Imaging, 47, 1147, 10.1007/s00259-019-04615-x Mu, 2020, Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy, Eur J Nucl Med Mol Imaging, 47, 1168, 10.1007/s00259-019-04625-9 Yoon, H. J. et al. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PLoS One 15, 1–13 (2020). Nardone, 2020, Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab, Oncol. Lett., 19, 1559 Castello, 2020, The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors, J Cancer Res Clin Oncol, 146, 1235, 10.1007/s00432-020-03150-9 Polverari, 2020, 18F-FDG pet parameters and radiomics features analysis in advanced nsclc treated with immunotherapy as predictors of therapy response and survival, Cancers (Basel), 12, 1163, 10.3390/cancers12051163 Wu, 2020, PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer, EJNMMI Res, 10, 10.1186/s13550-020-00639-9 Lopci, 2016, Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery, Eur J Nucl Med Mol Imaging, 43, 1954, 10.1007/s00259-016-3425-2 Grossmann, P. et al. Defining the biological basis of radiomic phenotypes in lung cancer. Elife 6, 1–22; 2017. Tang, C. et al. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci. Rep. 8, 1–9; 2018. Takada, 2017, Association between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer, Anticancer Res, 37, 7073 Sun, 2018, A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, 19, 1180, 10.1016/S1470-2045(18)30413-3 Kaira, 2018, Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC, Eur J Nucl Med Mol Imaging, 45, 56, 10.1007/s00259-017-3806-1 Khorrami, 2020, Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer, Cancer Immunol. Res., 8, 108, 10.1158/2326-6066.CIR-19-0476 Trebeschi, 2019, Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers, Ann Oncol, 30, 998, 10.1093/annonc/mdz108 Gevaert, 2014, Glioblastoma multiforme: Exploratory radiogenomic analysis by using quantitative image features, Radiology, 273, 168, 10.1148/radiol.14131731 Jamshidi, 2014, Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation, Radiology, 270, 1, 10.1148/radiol.13130078 Grossmann, 2016, Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma, BMC Cancer, 16, 1, 10.1186/s12885-016-2659-5 Jajamovich, 2016, Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma, J Neurooncol, 129, 289, 10.1007/s11060-016-2174-1 Rao, 2016, A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma, J Neurosurg, 124, 1008, 10.3171/2015.4.JNS142732 Narang, 2017, Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma, Oncotarget, 8, 101244, 10.18632/oncotarget.20643 Liu, 2018, A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas, NeuroImage Clin., 20, 1070, 10.1016/j.nicl.2018.10.014 Cho, 2018, Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis, Sci Rep, 8, 1, 10.1038/s41598-018-34242-9 Liu, 2018, Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas, Cancer Med., 7, 4273, 10.1002/cam4.1672 Cuccarini, 2019, Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma, J Clin Med, 8, 2007, 10.3390/jcm8112007 Ku, 2016, Correlation between MRI and the level of tumor-infltrating lymphocytes in patients with triple-negative breast cancer, Am J Roentgenol, 207, 1146, 10.2214/AJR.16.16248 Ku, 2018, Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis, J Magn Reson Imaging, 47, 760, 10.1002/jmri.25802 Yu, 2020, Correlation Between Mammographic Radiomics Features and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer, Front Oncol, 10, 1 Braman, 2019, Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer, JAMA Netw. open, 2, e192561, 10.1001/jamanetworkopen.2019.2561 Wu, 2017, Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with dysregulated signaling pathways and poor survival in breast cancer, Radiology, 285, 401, 10.1148/radiol.2017162823 Wu, 2018, Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer, Breast Cancer Res, 20, 1, 10.1186/s13058-018-1039-2 Fogante, 2019, Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer, Radiol. Medica, 124, 581, 10.1007/s11547-019-01008-w Yeh, 2019, Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling, Cancer Imaging, 19, 10.1186/s40644-019-0233-5 Çelebi, 2020, Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer, Eur Radiol, 30, 2049, 10.1007/s00330-019-06516-x Hectors, 2017, Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging, Sci Rep, 7, 1, 10.1038/s41598-017-02706-z Chen, 2019, Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging, Eur Radiol, 29, 4177, 10.1007/s00330-018-5986-x Liao, 2019, Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography, Ann Surg Oncol, 26, 4537, 10.1245/s10434-019-07815-9 Hectors, 2020, MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma, Eur Radiol, 30, 3759, 10.1007/s00330-020-06675-2 Bhatia, A. et al. Neuro-Oncology in melanoma brain metastases treated with immune checkpoint inhibitors. 1–9; 2019. doi:10.1093/neuonc/noz141. Basler, L. et al. Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition. Clin. Cancer Res. clincanres.0020.2020 (2020). doi:10.1158/1078-0432.ccr-20-0020 Seban, 2020, Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4, Eur J Nucl Med Mol Imaging, 47, 2301, 10.1007/s00259-020-04757-3 Wong, 2020, 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma, Cancer Imaging, 20, 10.1186/s40644-020-00313-2 Swartz, 2018, Influence of tumor and microenvironment characteristics on diffusion-weighted imaging in oropharyngeal carcinoma: A pilot study, Oral Oncol, 77, 9, 10.1016/j.oraloncology.2017.12.001 Zhu, 2019, Imaging-Genomic Study of Head and Neck Squamous Cell Carcinoma: Associations Between Radiomic Phenotypes and Genomic Mechanisms via Integration of The Cancer Genome Atlas and The Cancer Imaging Archive, JCO Clin. cancer informatics, 3, 1, 10.1200/CCI.18.00073 Tixier, 2020, Transcriptomics in cancer revealed by Positron Emission Tomography radiomics, Sci Rep, 10, 1, 10.1038/s41598-020-62414-z Gao, X. et al. A CT-based radiomics signature for evaluating tumor infiltrating Treg cells and outcome prediction of gastric cancer. Ann Transl Med 8, 469–469; 2020. Park, 2020, Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma, Eur Radiol, 30, 5392, 10.1007/s00330-020-06847-0 Kuriyama, 2020, Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma, Cancer Sci, 111, 1969, 10.1111/cas.14421 Lim, 2018, Current state of immunotherapy for glioblastoma, Nat Rev Clin Oncol, 15, 422, 10.1038/s41571-018-0003-5 Li, 2016, Comprehensive analyses of tumor immunity: implications for cancer immunotherapy, Genome Biol, 17, 174, 10.1186/s13059-016-1028-7 Chen, 2013, The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis, PLoS ONE, 8, e79008, 10.1371/journal.pone.0079008 Adams, 2019, Current Landscape of Immunotherapy in Breast Cancer, JAMA Oncol, 5, 1205, 10.1001/jamaoncol.2018.7147 Mohammed, 2012, The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer, Br J Cancer, 107, 864, 10.1038/bjc.2012.347 Stanton, 2016, Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes, JAMA Oncol., 2, 1354, 10.1001/jamaoncol.2016.1061 Rooney, 2015, Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity, Cell, 160, 48, 10.1016/j.cell.2014.12.033 van de Donk, 2020, Molecular imaging biomarkers for immune checkpoint inhibitor therapy, Theranostics, 10, 1708, 10.7150/thno.38339 Ferris, 2016, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Mehra, 2018, Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012, Br J Cancer, 119, 153, 10.1038/s41416-018-0131-9 Mandal, R. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1; 2016. Shukuya, T. & Carbone, D. P. Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer. J. Thorac. Oncol. 11, 976–988; 2016. Scalco, 2020, T2w-MRI signal normalization affects radiomics features reproducibility, Med Phys, 47, 1680, 10.1002/mp.14038 Zwanenburg, A., Leger, S., Vallières, M. & Löck, S. Image biomarker standardisation initiative. arXiv Prepr. arXiv1612.07003; 2016. van Griethuysen, 2017, Computational Radiomics System to Decode the Radiographic Phenotype, Cancer Res, 77, e104, 10.1158/0008-5472.CAN-17-0339 Apte, 2018, Technical Note : Extension of CERR for computational radiomics: a comprehensive MATLAB platform for reproducible radiomics research, Med Phys, 10.1002/mp.13046 Nioche, 2018, LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity, Cancer Res, 78, 4786, 10.1158/0008-5472.CAN-18-0125 Dinapoli, N. et al. Moddicom: a complete and easily accessible library for prognostic evaluations relying on image features. in 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 771–774 (IEEE, 2015). doi:10.1109/EMBC.2015.7318476 Zhang, 2015, IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics, Med Phys, 42, 1341, 10.1118/1.4908210 Götz, 2019, MITK Phenotyping: An open-source toolchain for image-based personalized medicine with radiomics, Radiother Oncol, 131, 108, 10.1016/j.radonc.2018.11.021 Pavic, 2018, Influence of inter-observer delineation variability on radiomics stability in different tumor sites, Acta Oncol. (Madr), 57, 1070, 10.1080/0284186X.2018.1445283 Traverso, 2018, Repeatability and reproducibility of radiomic features: a systematic review, Int J Radiat Oncol Biol Phys, 102, 1143, 10.1016/j.ijrobp.2018.05.053 Park, 2019, Reproducibility and generalizability in radiomics modeling: possible strategies in radiologic and statistical perspectives, Korean J Radiol, 20, 1124, 10.3348/kjr.2018.0070 Owens, 2018, Lung tumor segmentation methods: Impact on the uncertainty of radiomics features for non-small cell lung cancer, PLoS ONE, 13, e0205003, 10.1371/journal.pone.0205003 Hosny, 2019, Handcrafted versus deep learning radiomics for prediction of cancer therapy response, Lancet Digit Heal, 1, e106, 10.1016/S2589-7500(19)30062-7 Parekh, 2019, Deep learning and radiomics in precision medicine, Expert Rev. Precis Med drug Dev, 4, 59, 10.1080/23808993.2019.1585805 Vial, 2018, The role of deep learning and radiomic feature extraction in cancer-specific predictive modelling: a review, Transl. Cancer Res, 7, 803, 10.21037/tcr.2018.05.02 Lou, 2019, An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction, Lancet Digit Heal, 1, e136, 10.1016/S2589-7500(19)30058-5 Chalkidou, 2015, False discovery rates in PET and CT studies with texture features: a systematic review, PLoS ONE, 10, e0124165, 10.1371/journal.pone.0124165 Nguyen, 2019, quick tips for effective dimensionality reduction, PLoS Comput Biol, 15, 10.1371/journal.pcbi.1006907 Stoyanov, 2018 Simonyan, K., Vedaldi, A. & Zisserman, A. Deep inside convolutional networks: Visualising image classification models and saliency maps. arXiv Prepr. arXiv1312.6034 (2013). De Fauw, 2018, Clinically applicable deep learning for diagnosis and referral in retinal disease, Nat Med, 24, 1342, 10.1038/s41591-018-0107-6 Saltz, 2018, Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images, Cell Rep., 23, 181, 10.1016/j.celrep.2018.03.086 Zhang, 2014, Proteogenomic characterization of human colon and rectal cancer, Nature, 513, 382, 10.1038/nature13438 Mertins, 2016, Proteogenomics connects somatic mutations to signalling in breast cancer, Nature, 534, 55, 10.1038/nature18003 Zhang, 2016, Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069 Vasaikar, 2019, Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities, Cell, 177, 1035, 10.1016/j.cell.2019.03.030 Zanfardino, 2019, Bringing radiomics into a multi-omics framework for a comprehensive genotype–phenotype characterization of oncological diseases, J. Transl. Med., 17, 1, 10.1186/s12967-019-2073-2 Foster, MSLS, E. D. & Deardorff, MLIS, A. Open Science Framework (OSF). J. Med. Libr. Assoc. 105, (2017). Clark, 2013, The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository, J Digit Imaging, 26, 1045, 10.1007/s10278-013-9622-7 Sullivan, 2015, Metrology standards for quantitative imaging biomarkers, Radiology, 277, 813, 10.1148/radiol.2015142202 Moons, 2015, Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration, Ann Intern Med, 162, W1, 10.7326/M14-0698 Conesa, 2016, A survey of best practices for RNA-seq data analysis, Genome Biol, 17, 13, 10.1186/s13059-016-0881-8 Salgado, 2015, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann Oncol, 26, 259, 10.1093/annonc/mdu450